How did Purple Biotech's expenses trend in Q4 2024?

In Q4 2024, Purple Biotech's expenses showed a notable increase in Research and Development (R&D) and Selling, General, and Administrative (SG&A) costs, reflecting the company's heightened investment in innovation and business development activities. 1. **Research and Development (R&D) Expenses**: The R&D expenses for Purple Biotech in Q4 2024 were $458,000. This indicates a strong commitment to advancing its product pipeline and technological developments. |code|Ticker|Name|Date|R&D Expenses|Operating Expenses|Advertising and Marketing Expenses|market_code| |---|---|---|---|---|---|---|---| |PPBT|PPBT.O|Purple Biotech|2024 Q1|3423000|||186| |PPBT|PPBT.O|Purple Biotech|2024 Q2|2391000|||186| |PPBT|PPBT.O|Purple Biotech|2024 Q3|1348000|||186| |PPBT|PPBT.O|Purple Biotech|2024 Q4|458000|||186| 2. **Selling, General, and Administrative (SG&A) Expenses**: Concurrently, the SG&A expenses reached $558,000. This suggests a strategic expansion in sales and marketing efforts, as well as increased administrative activities to support the company's growth and operational scale. 3. **Trend Analysis**: The combined R&D and SG&A expenses for Q4 2024 amount to $1,016,000. This figure represents a significant investment in both innovation and business development, which is a positive signal for the company's future prospects, assuming these efforts lead to successful product launches and market expansion. Overall, Purple Biotech's expense trend in Q4 2024 reflects a proactive approach to growth, with substantial investments in R&D and SG&A activities that are likely to have a lasting impact on the company's trajectory.